Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced ...

Preliminary results from the AACR 2025 Annual Meeting reveal encouraging clinical responses to the investigational oral agent ...

A new combination therapy has been found to give better results for patients with a certain type of colorectal cancer that no ...

Croatian confectionery producer Kras [ZSE:<a href=" target="_blank">KRAS] said on Wednesday it has proposed to shareholders ...

“This trial is the first time we’ve ever seen this kind of benefit in treating non-small cell lung cancers caused by KRAS-G12D,” Dr. Arbour says. “What we saw in these patients is dramatically ...

KRAS G12C inhibitors mark a breakthrough in oncology, but resistance is driving the need for smarter preclinical models and ...

HonorHealth Research Institute's new downtown Phoenix laboratory has produced its first study, centered on a promising new ...

Preclinical data demonstrates synergy of QTX3544 with EGFR inhibitors, broadly enhancing anti-tumor activity - - Data supports ongoing Phase 1 clinical trial for QTX3544 as monotherapy and in ...

First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE ...